Rapid responses are electronic comments to the editor. They enable our users to debate issues raised in articles published on bmj.com. A rapid response is first posted online. If you need the URL (web address) of an individual response, simply click on the response headline and copy the URL from the browser window. A proportion of responses will, after editing, be published online and in the print journal as letters, which are indexed in PubMed. Rapid responses are not indexed in PubMed and they are not journal articles. The BMJ reserves the right to remove responses which are being wilfully misrepresented as published articles.
We would like to draw your attention to an error in this article relating to the status of oseltamivir on the WHO Model List of Essential Medicines.
The author has incorrectly stated that oseltamivir was removed from the Model List, citing Ebell (2017) . A correction to this source paper was subsequently published: https://www.bmj.com/content/359/bmj.j5281.
The listing of oseltamivir on the Model List was reviewed and amended in 2017 by the WHO Expert Committee on Selection and Use of Essential Medicines. Oseltamivir was transferred from the core to the complementary list, with its use restricted to severe illness due to confirmed or suspected influenza virus infection in critically ill hospitalized patients. It was also proposed that oseltamivir could be considered for deletion in 2019 should no new information be provided to support the use of oseltamivir in seasonal and pandemic outbreaks. Details of this review and amendment are available in the technical report of the 2017 Expert Committee meeting at https://apps.who.int/iris/handle/10665/259481.
In 2019, the Expert Committee noted that WHO Guidelines for clinical management of influenza were being updated, but the recommendations of the guideline development group were not yet available. The Committee recommended that no change be made to the current listing for oseltamivir on the Model Lists until the updated guidelines and supporting evidence can be reviewed. The technical report of the 2019 Expert Committee meeting is available at https://apps.who.int/iris/handle/10665/330668.
Bernadette Cappello and Lorenzo Moja
WHO Essential Medicines List Secretariat
No competing interests
22 July 2020
Bernadette M Cappello
Department of Health Products Policy and Standards, World Health Organization